Brief: Sanofi’s Rezurock Approved In The EU To Treat Chronic Graft-vs-host Disease
31/03/2026 06:03
March 31 (Reuters) - Sanofi SA SASY.PA: REZUROCK APPROVED IN THE EU TO TREAT CHRONIC GRAFT-VERSUS-HOST DISEASE REZUROCK INDICATED WHEN OTHER CHRONIC GVHD TREATMENTS ARE LIMITED OR EXHAUSTED Source text: ID: nGNXjrHV9 Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes